Clinical trials · North Carolina
Alzheimer’s disease clinical trials in North Carolina
We’re tracking 31 recruiting alzheimer’s disease studies with a site in North Carolina — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
Winston-Salem, North CarolinaAges 55–80 - NCT05010603Recruiting
Studies families to understand late-onset Alzheimer’s
This study focuses on people with late-onset Alzheimer’s (and some similar memory diseases) and uses a close family “informant” to share what they’ve noticed. It may help researchers learn more about these conditions and how they progress in families.
Raleigh, North CarolinaAges 55 years+ - NCT05462106RecruitingPhase 1/Phase 2
ACI-24.060 study for early Alzheimer’s in adults and Down syndrome
This Phase 1/2 study tests an Alzheimer’s treatment called ACI-24.060 to see if it affects the disease in people with early Alzheimer’s changes. It includes two groups: older adults with early symptoms and people with Down syndrome who also show Alzheimer’s-related changes on brain scans.
Matthews, North CarolinaAges 35–85 - NCT06565169Recruiting
Helping primary care doctors support advance care planning for dementia
This study tests a training tool to help primary care teams talk about future care wishes with people who have Alzheimer's or related dementias. It aims to improve advance care planning for older adults with dementia.
Chapel Hill, North CarolinaAges 18–99 - NCT06297590RecruitingPhase 1
First human study of a new Alzheimer's drug
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Durham, North CarolinaAges 50–85 - NCT06703541Recruiting
Alzheimer's disease research study with brain scans and spinal tap
This study at Duke University is looking for people aged 25 to 80 who may be at risk for Alzheimer's disease. It involves brain scans (MRI and PET) and a spinal tap to learn more about the disease and find better ways to detect and treat it early.
Durham, North CarolinaAges 25–80 - NCT07169578RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests a new drug called trontinemab for people with early Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
Greensboro, North CarolinaAges 50–90 - NCT03089827Enrolling by invitation
Tests how a brain imaging tracer spreads in Alzheimer’s risk
This trial uses a radioactive imaging tracer to see how it moves and settles in the brain in people with risk factors for Alzheimer’s disease. It may help researchers understand which people show tracer patterns linked to Alzheimer’s changes.
Winston-Salem, North CarolinaAges 55 years+ - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Greensboro, North CarolinaAges 50–90 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Matthews, North CarolinaAges 60–85 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Charlotte, North CarolinaAges 55–90 - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Morehead City, North CarolinaAges 55–90 - NCT06657768RecruitingPhase 1
Study of LY4006895 for healthy people and those with early Alzheimer's
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Durham, North CarolinaAges 45–85 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Chapel Hill, North CarolinaAges 50–85 - NCT07105709RecruitingPhase 2
Extension study for early Alzheimer's treatment
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Matthews, North CarolinaAges 50–85 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Morehead City, North CarolinaAges 55–90 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Greensboro, North CarolinaAges 55–90 - NCT03140865Recruiting
Alzheimer’s disease research core for brain and memory testing
This study group collects detailed information from people with normal memory, mild cognitive impairment, or mild Alzheimer’s disease to support Alzheimer’s research. You may need multiple visits, brain scans, and sometimes a spinal fluid sample, with strict health and medication requirements to keep results clear.
Winston-Salem, North CarolinaAges 55 years+ - NCT06840587Recruiting
Connect-Home: Alzheimer's and related dementias study
This trial tests a program to help people with dementia and their caregivers prepare for a safe move from a skilled nursing facility to home or another care setting. It aims to improve the transition and support both the patient and caregiver.
Chapel Hill, North CarolinaAges 19 years+ - NCT06540833RecruitingPhase 2
Study of ITI-1284 for psychosis in Alzheimer's disease
This trial tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis (hallucinations or delusions) in people with Alzheimer's disease. It may be an option for patients who have both Alzheimer's and related psychotic symptoms.
Charlotte, North CarolinaAges 55 years+ - NCT06245031Enrolling by invitation
Long-term follow-up of sensory stimulation for Alzheimer's
This is a follow-up study for people who already completed the 12-month Hope Study (CA-0011). It tests long-term safety and effects of a gentle sensory stimulation device (light and sound) for Alzheimer's disease. You will continue using the device at home with a study partner.
Matthews, North CarolinaAges 50–92 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Matthews, North CarolinaAges 50–85 - NCT05973448Enrolling by invitation
Nightlight Falls Prevention for People With Dementia
This study tests a simple plan to help prevent falls in people who have dementia. You may be able to join if you live in a participating assisted living community and meet the safety and room rules.
Chapel Hill, North CarolinaAges 18 years+ - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
Durham, North CarolinaAges 55–90
Alzheimer’s disease trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- AMC Research, LLC · 4 studies
- Triad Clinical Trials · 3 studies
- University of North Carolina at Chapel Hill · 3 studies
- West Clinical Research · 3 studies
- Atrium Health Wake Forest Baptist Medical Center (Wake Forest Baptist) · 2 studies
- Duke University · 2 studies
- New Hope Clinical Research · 2 studies
- Wake Forest University Health Sciences · 2 studies
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Alzheimer’s disease trials in other states
Common questions
- Are there alzheimer’s disease clinical trials in North Carolina?
- Yes. We're currently tracking 31 recruiting alzheimer’s disease studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.